A new article published in Cephalgia (Pubmed abstract below) showed that Sphenopalatine Ganglion (SPG) Stimulation reduces prescription costs in Cluster Heradaches by more than half. These were treatment resistant patients!
Spenopalatine Ganglion Blocks are far more effective than microstimultion but require trips to the doctor or ER. The best approach to Cluster Headaches is Self-Administration of Sphenopalatine Ganglion (SPG) Blocks
Self-Administration can dramatically improve the quality of life of Cluster headache patients and almost eliminate the need of medication.
Self administered SPG Blocks are incredible cost effective both for treatment and prevention of cluster headaches. More important they avoid the need for visits to doctors offices or emergency departments. The cost is less than $1.00. Quality of life improvement is priceless.
Sphenopalatine Ganglion Blocks have also been shown to be effective for Status Migrainosus: Sphenopalatine
Side effects of Sphenopalatine Ganglion Blocks include DECREASED ANXIETY and Pain. There is excellent evidence for using SPG Blocks to treat (eliminate) newly diagnosed essential hypertension and PTSD.
Dr Shapira see patients from across the United States who want to learn to Self-Administer SPG Blocks. He uses them in conjunction with Neuromuscular Dentistry to change peoples quality of life.
Visit his website www.ThinkBetterLife.com to learn more.
The Think Better Life YouTube Channel has over 150 patient testimonial videos.
Cephalalgia. 2018 Jul;38(8):1455-1462. doi: 10.1177/0333102418784689. Epub 2018 Jun 19.
Changes in medication cost observed in chronic cluster headache patients treated with sphenopalatine ganglion (SPG) stimulation: Analysis based on 1-year data from the Pathway R-1 Registry.
Pietzsch JB1, Weber SA2, Lund N3, Gaul C4.
Background On-demand stimulation of the sphenopalatine ganglion (SPG) by means of an implantable neurostimulation system has been shown to be a safe and effective therapy for treatment-refractory cluster headache patients. Our objective was to estimate changes in cluster headache medication cost observed in SPG-treated chronic patients. Methods Detailed patient-level data of 71 chronic patients treated with the Pulsante® SPG Microstimulator System were available from the Pathway R-1 Registry through 12 months’ follow-up. We used utilization data of preventive and acute medications reported at baseline, 3, 6, 9, and 12 months to estimate annualized drug costs for SPG-treated patients and compared it to baseline. Cost estimates for all drug/dosage combinations were developed based on German medication prices for 2016. Results In the base case analysis, mean annual acute and preventive medication costs decreased from €14,178 to €6924 (-€7254; -51%), and €559 to €328 (-€231; -41%), respectively, leading to total estimated annual drug cost savings of €7484, 97% of which were attributable to acute medications. Conclusions Our analysis suggests that SPG stimulation for the treatment of chronic cluster headache is associated with pronounced reductions in cluster headache medication usage that might lead to sizable annual savings in medication costs.
Chronic cluster headache; Germany; cost-analysis; implantable stimulator; medication costs; sphenopalatine ganglion